Robust performance of generics in H1 19
14/08/19 -"Hikma reported a strong performance in H1 19, with revenue growth of 8% (at CER), primarily attributable to a better-than-expected performance of Generics (+11%), along with an in line performance of ..."
Pages
48
Language
English
Published on
14/08/19
You may also be interested by these reports :
13/05/24
Lundbeck’s 2023 profitability fell short of our expectations as, despite some yoy improvement, margins were under pressure from higher SG&A related ...
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...